Ocular Therapeutix, Inc. (OCUL)
6.205
-0.08
(-1.19%)
USD |
NASDAQ |
Nov 13, 16:00
6.20
0.00 (0.00%)
After-Hours: 19:59
Ocular Therapeutix Enterprise Value : 930.28M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 930.28M |
| November 11, 2026 | 1.014B |
| November 10, 2026 | 1.003B |
| November 09, 2026 | 1.056B |
| November 06, 2026 | 999.54M |
| November 05, 2026 | 963.26M |
| November 04, 2026 | 1.119B |
| November 03, 2026 | 1.049B |
| November 02, 2026 | 1.029B |
| October 30, 2026 | 1.082B |
| October 29, 2026 | 1.157B |
| October 28, 2026 | 1.152B |
| October 27, 2026 | 1.027B |
| October 26, 2026 | 972.06M |
| October 23, 2026 | 978.65M |
| October 22, 2026 | 1.003B |
| October 21, 2026 | 974.26M |
| October 20, 2026 | 1.012B |
| October 19, 2026 | 932.48M |
| October 16, 2026 | 1.060B |
| October 15, 2026 | 1.172B |
| October 14, 2026 | 1.133B |
| October 13, 2026 | 1.141B |
| October 12, 2026 | 1.212B |
| October 09, 2026 | 1.207B |
| Date | Value |
|---|---|
| October 08, 2026 | 1.201B |
| October 07, 2026 | 1.139B |
| October 06, 2026 | 1.163B |
| October 05, 2026 | 1.144B |
| October 02, 2026 | 1.080B |
| October 01, 2026 | 1.152B |
| September 30, 2026 | 1.236B |
| September 29, 2026 | 1.209B |
| September 28, 2026 | 1.162B |
| September 25, 2026 | 1.600B |
| September 24, 2026 | 1.637B |
| September 23, 2026 | 1.677B |
| September 22, 2026 | 1.786B |
| September 21, 2026 | 1.674B |
| September 18, 2026 | 1.674B |
| September 17, 2026 | 1.707B |
| September 16, 2026 | 1.648B |
| September 15, 2026 | 1.718B |
| September 14, 2026 | 1.835B |
| September 11, 2026 | 1.784B |
| September 10, 2026 | 1.813B |
| September 09, 2026 | 1.999B |
| September 08, 2026 | 1.977B |
| September 04, 2026 | 1.817B |
| September 03, 2026 | 1.817B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| EyePoint, Inc. | -71.94M |
| ANI Pharmaceuticals, Inc. | 1.798B |
| Eli Lilly & Co. | 1.388T |
| Corcept Therapeutics, Inc. | 7.700B |
| Veru, Inc. | 13.04M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -94.78M |
| Revenue (Quarterly) | 12.87M |
| Total Expenses (Quarterly) | 107.66M |
| EPS Diluted (Quarterly) | -0.4203 |
| Gross Profit Margin (Quarterly) | 79.17% |
| Profit Margin (Quarterly) | -736.2% |
| Earnings Yield | -23.46% |
| Normalized Earnings Yield | -23.65 |